Additionally, six of 21 (28.6%) BCL-2− AML patients showed a WBC count of ≥25 × 109/L, an important marker of proliferative disease [24], as compared with 24 of 72 patients (33.3%) in the BCL-2+ subgroup. The gene discussed is BCL2; the disease is acute myeloid leukemia.